表紙
市場調查報告書

關注市場分析:急性淋巴性白血病 (ALL)

Market Spotlight: Acute Lymphoblastic Leukemia (ALL)

出版商 Datamonitor Healthcare 商品編碼 917493
出版日期 內容資訊 英文 58 Pages
商品交期: 最快1-2個工作天內
價格
關注市場分析:急性淋巴性白血病 (ALL) Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
出版日期: 2020年02月03日內容資訊: 英文 58 Pages
簡介

本報告提供急性淋巴性白血病 (ALL的)治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的治療方法,法規環境和近幾年主要的事件,現在開發中臨床實驗的進展上市計劃,主要的治療藥的市場趨勢預測,資本交易的動向等調查。

概要

要點

疾病的背景情況

  • 定義
  • 患者區分
  • 症狀
  • 風險因素
  • 診斷

治療方法

  • 化療
  • 皮質類固醇
  • TKI療法
  • 免疫療法
  • 放射線治療
  • 幹細胞移植

流行病學

已上市醫藥品

開發平台藥物

最新活動、分析師的見解

  • Blincyto
  • Copiktra
  • KTE-X19
  • Copiktra
  • Marqibo
  • AFM11
  • KTE-X19
  • AUTO3
  • Xpovio
  • AFM11
  • ERY-ASP
  • KTE-X19

不久將來的活動

法規相關的主要活動

成功的可能性

授權合約、資產收購交易

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各階段 (相位)
  • 近幾年趨勢

相關分析

  • 處方藥的資訊

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0207213

This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

Datamonitor Healthcare estimates that in 2018, there were 86,600 incident cases of acute lymphoblastic leukemia (ALL) worldwide, and expects that number to increase to 93,500 incident cases by 2027.

Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.

The majority of industry-sponsored drugs in active clinical development for ALL are in Phase I, with two drugs in Phase III. Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route.

The only high-impact upcoming event for drugs in the ALL space is topline Phase II trial results for Sarclisa. The overall likelihood of approval of a Phase I hematologic asset is 10%, and the average probability a drug advances from Phase III is 59.6%. Drugs, on average, take 8.9 years from Phase I to approval, compared to 9.3 years in the overall oncology space.

There have been 32 licensing and asset acquisition deals involving ALL drugs during 2015-20. The $2,000m collaboration and license agreement signed in January 2020 between MorphoSys and Incyte to further develop and commercialize MorphoSys' proprietary anti-CD19 antibody, MOR208 (tafasitamab), globally was the largest deal.

The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for ALL have been in the early and midphases of development, with 91% of trials in Phase I-II, and only 9% in Phase III-IV.

The US has a substantial lead in the number of ALL clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.

Novartis has the highest number of completed clinical trials for ALL, with 41 trials.

Novartis leads industry sponsors with the highest overall number of clinical trials for ALL.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Definition
  • Patient segmentation
  • Symptoms
  • Risk factors
  • Diagnosis

TREATMENT

  • Chemotherapy
  • Corticosteroids
  • TKI therapy
  • Immunotherapy
  • Radiation therapy
  • Stem cell transplant

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Blincyto for ALL (December 10, 2019)
  • GC022 for ALL (December 7, 2019)
  • Blincyto for ALL (September 24, 2019)
  • Copiktra for ALL (July 25, 2019)
  • KTE-X19 for ALL (June 1, 2019)
  • Copiktra for ALL (March 6, 2019)
  • Marqibo for ALL (January 17, 2019)
  • AFM11 for ALL (December 3, 2018)
  • KTE-X19 for ALL (December 3, 2018)
  • AUTO3 for ALL (December 2, 2018)
  • Xpovio for ALL (December 1, 2018)
  • AFM11 for ALL (October 8, 2018)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Japan Approvals Include World-First For Skyrizi, Kymriah As Asia's First CAR-T

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Pascal, Y-Biologics Ink Bispecific Collaboration For Leukemia
  • CASI Acquires Global Rights To Juventas' Anti-CD19 Therapy

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of ALL, 2018-27
  • Figure 2: Overview of pipeline drugs for ALL in the US
  • Figure 3: Pipeline drugs for ALL, by company
  • Figure 4: Pipeline drugs for ALL, by drug type
  • Figure 5: Pipeline drugs for ALL, by classification
  • Figure 6: Blincyto for ALL (September 24, 2019): Phase III - Pediatric (1st Relapse)
  • Figure 7: KTE-X19 for ALL (June 1, 2019): Phase I/II - ZUMA-3 (r/r Adults)
  • Figure 8: KTE-X19 for ALL (December 3, 2018): Phase I/II - ZUMA-3 (r/r Adults)
  • Figure 9: Key upcoming events in ALL
  • Figure 10: Probability of success in the ALL pipeline
  • Figure 11: Licensing and asset acquisition deals in ALL, 2015-20
  • Figure 12: Parent patents in ALL
  • Figure 13: Clinical trials in ALL
  • Figure 14: Top 10 drugs for clinical trials in ALL
  • Figure 15: Top 10 companies for clinical trials in ALL
  • Figure 16: Trial locations in ALL
  • Figure 17: ALL trials sponsors by status
  • Figure 18: ALL trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of ALL, 2018-27
  • Table 2: Marketed drugs for ALL
  • Table 3: Pipeline drugs for ALL in the US
  • Table 4: Blincyto for ALL (December 10, 2019)
  • Table 5: GC022 for ALL (December 7, 2019)
  • Table 6: Blincyto for ALL (September 24, 2019)
  • Table 7: Copiktra for ALL (July 25, 2019)
  • Table 8: KTE-X19 for ALL (June 1, 2019)
  • Table 9: Copiktra for ALL (March 6, 2019)
  • Table 10: Marqibo for ALL (January 17, 2019)
  • Table 11: AFM11 for ALL (December 3, 2018)
  • Table 12: KTE-X19 for ALL (December 3, 2018)
  • Table 13: AUTO3 for ALL (December 2, 2018)
  • Table 14: Xpovio for ALL (December 1, 2018)
  • Table 15: AFM11 for ALL (October 8, 2018)
  • Table 16: Historical global sales, by drug ($m), 2014-18
  • Table 17: Forecasted global sales, by drug ($m), 2020-24